Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Randomized, Rater- and Dose-Blinded Study Comparing Two Annual Cycles of Intravenous Low- and High-Dose Alemtuzumab to Three-Times Weekly Subcutaneous Interferon Beta 1a (Rebif®) in Patients With Relapsing Remitting Multiple Sclerosis Who Have Relapsed On Therapy
Brief Summary: The purpose of this study was to establish the efficacy and safety of two different doses of alemtuzumab (Lemtrada™) as a treatment for relapsing-remitting multiple sclerosis (MS), in comparison with subcutaneous interferon beta-1a (Rebif®). The study enrolled participants who had received an adequate trial of disease-modifying therapies but experienced at least 1 relapse during prior treatment, and who met a minimum severity of disease as measured by magnetic resonance imaging (MRI). Participants had monthly laboratory tests and comprehensive testing every 3 months.


Options:
A: Arm Label: Group 1 Standard Immunosuppression; Type: N/A; Interventions: N/A | Arm Label: Group 2 Campath Immunosuppression; Type: N/A; Interventions: N/A
B: Arm Label: Group 1; Type: EXPERIMENTAL; Interventions: Drug: rabbit anti-thymocyte globulin - single dose, Drug: sirolimus, Drug: tacrolimus | Arm Label: Group 2; Type: EXPERIMENTAL; Interventions: Drug: rabbit anti-thymocyte globulin - 4 doses, Drug: sirolimus, Drug: tacrolimus | Arm Label: Group 3; Type: EXPERIMENTAL; Interventions: Drug: rabbit anti-thymocyte globulin - single dose, Drug: mycophenolate mofetil, Drug: sirolimus, Drug: tacrolimus | Arm Label: Group 4; Type: EXPERIMENTAL; Interventions: Drug: mycophenolate mofetil, Drug: rabbit anti-thymocyte globulin - 4 doses, Drug: sirolimus, Drug: tacrolimus | Intervention Type: DRUG; Name: rabbit anti-thymocyte globulin - single dose; Assigned to Arm(s): Group 1, Group 3 | Intervention Type: DRUG; Name: mycophenolate mofetil; Assigned to Arm(s): Group 3, Group 4 | Intervention Type: DRUG; Name: rabbit anti-thymocyte globulin - 4 doses; Assigned to Arm(s): Group 2, Group 4 | Intervention Type: DRUG; Name: sirolimus; Assigned to Arm(s): Group 1, Group 2, Group 3, Group 4 | Intervention Type: DRUG; Name: tacrolimus; Assigned to Arm(s): Group 1, Group 2, Group 3, Group 4
C: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Thymoglobulin | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: Campath-1H | Arm Label: C; Type: EXPERIMENTAL; Interventions: Drug: Daclizumab | Intervention Type: DRUG; Name: Thymoglobulin; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Campath-1H; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Daclizumab; Assigned to Arm(s): C
D: Arm Label: Alemtuzumab 12 mg; Type: EXPERIMENTAL; Interventions: Biological: Alemtuzumab 12 mg | Arm Label: Alemtuzumab 24 mg; Type: EXPERIMENTAL; Interventions: Biological: Alemtuzumab 24 mg | Arm Label: Interferon Beta-1a; Type: ACTIVE_COMPARATOR; Interventions: Biological: Interferon beta-1a | Intervention Type: BIOLOGICAL; Name: Alemtuzumab 12 mg; Assigned to Arm(s): Alemtuzumab 12 mg | Intervention Type: BIOLOGICAL; Name: Alemtuzumab 24 mg; Assigned to Arm(s): Alemtuzumab 24 mg | Intervention Type: BIOLOGICAL; Name: Interferon beta-1a; Assigned to Arm(s): Interferon Beta-1a

Answer: D